Vol 5, No 6 (2004): Practical Diabetology
Research paper
Published online: 2005-02-02
Apoptosis inhibitor sFas expression and acute hyperglycemia in type 2 diabetes
Diabetologia Praktyczna 2004;5(6):311-316.
Abstract
INTRODUCTION. Apoptosis occuring via Fas/FasL interaction
is one from the reasons of macroangiopathy.
The soluble receptor Fas (sFas) is thought to be
an inhibitor of apoptosis. In type 2 diabetic patients
apoptosis is determined by the level of metabolic
compensation. The epidemiological studies from last
few years revealed that postprandial, so acute, hyperglycemia
plays the dominant role in coronary
heart disease development. We aimed to evaluate if
metabolic control and acute hyperglycemic episodes
especially, can influence sFas serum level.
MATERIAL AND METHODS. The total of 49 persons were examined, including 29 type 2 diabetic patients with concomitant coronary heart disease, 10 patients with coronary heart disease only and 10 healthy persons. The plasma level of 1.5-anhydro-D-glucitol was estimated as the marker of acute hyperglycemia. The serum sFas levels were measured together with routine metabolic parameters (fasting glycemia, HbA1c, total cholesterol and HDL, and LDL cholesterol fractions levels, triglyceride serum concentration).
RESULTS. The sFas serum level was significantly higher in patients with diabetes type 2 than in patients with coronary heart disease only and higher than sFas level in controls. The sFas serum concentration in type 2 diabetic patients was correlated only with 1.5-anhydro-D-glucitol concentration.
CONCLUSION. The short-term hyperglycemic episodes, in opposition to chronic hyperglycemia, are related to lower expression of antiapoptotic factor sFas.
MATERIAL AND METHODS. The total of 49 persons were examined, including 29 type 2 diabetic patients with concomitant coronary heart disease, 10 patients with coronary heart disease only and 10 healthy persons. The plasma level of 1.5-anhydro-D-glucitol was estimated as the marker of acute hyperglycemia. The serum sFas levels were measured together with routine metabolic parameters (fasting glycemia, HbA1c, total cholesterol and HDL, and LDL cholesterol fractions levels, triglyceride serum concentration).
RESULTS. The sFas serum level was significantly higher in patients with diabetes type 2 than in patients with coronary heart disease only and higher than sFas level in controls. The sFas serum concentration in type 2 diabetic patients was correlated only with 1.5-anhydro-D-glucitol concentration.
CONCLUSION. The short-term hyperglycemic episodes, in opposition to chronic hyperglycemia, are related to lower expression of antiapoptotic factor sFas.
Keywords: diabetes type 2apoptosisacute hyperglycemiasFas